Voyager Therapeutics (VYGR) Competitors $4.18 -0.20 (-4.57%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.25 +0.07 (+1.58%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. AMLX, CRMD, TRVI, TSHA, PHAT, IOVA, PRAX, AKBA, AVBP, and IMNMShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Amylyx Pharmaceuticals (AMLX), CorMedix (CRMD), Trevi Therapeutics (TRVI), Taysha Gene Therapies (TSHA), Phathom Pharmaceuticals (PHAT), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Akebia Therapeutics (AKBA), ArriVent BioPharma (AVBP), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Its Competitors Amylyx Pharmaceuticals CorMedix Trevi Therapeutics Taysha Gene Therapies Phathom Pharmaceuticals Iovance Biotherapeutics Praxis Precision Medicines Akebia Therapeutics ArriVent BioPharma Immunome Voyager Therapeutics (NASDAQ:VYGR) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends. Is VYGR or AMLX more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -253.49%. Voyager Therapeutics' return on equity of -37.65% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-253.49% -37.65% -28.89% Amylyx Pharmaceuticals N/A -82.48%-70.15% Which has more volatility & risk, VYGR or AMLX? Voyager Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500. Do analysts recommend VYGR or AMLX? Voyager Therapeutics presently has a consensus target price of $13.25, suggesting a potential upside of 216.92%. Amylyx Pharmaceuticals has a consensus target price of $12.25, suggesting a potential upside of 5.15%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, VYGR or AMLX? Voyager Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$42.58M5.45-$65M-$1.85-2.26Amylyx Pharmaceuticals$87.37M11.89-$301.74M-$2.50-4.66 Does the media favor VYGR or AMLX? In the previous week, Amylyx Pharmaceuticals had 11 more articles in the media than Voyager Therapeutics. MarketBeat recorded 13 mentions for Amylyx Pharmaceuticals and 2 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.81 beat Amylyx Pharmaceuticals' score of 1.03 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Amylyx Pharmaceuticals 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in VYGR or AMLX? 48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 6.4% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryVoyager Therapeutics beats Amylyx Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.95M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-2.2621.4375.4125.98Price / Sales5.45432.54515.86180.60Price / CashN/A46.6837.5660.44Price / Book0.769.6112.156.29Net Income-$65M-$53.29M$3.29B$271.07M7 Day Performance-1.42%0.13%0.74%3.87%1 Month Performance12.37%5.55%5.00%5.49%1 Year Performance-33.12%10.44%62.55%25.86% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics3.9424 of 5 stars$4.18-4.6%$13.25+216.9%-33.1%$242.95M$42.58M-2.26100Positive NewsAMLXAmylyx Pharmaceuticals1.7927 of 5 stars$10.44+2.4%$12.25+17.3%+344.7%$930.90M-$249K-4.18200Positive NewsCRMDCorMedix3.916 of 5 stars$12.75+2.8%$17.33+35.9%+86.2%$925.65M$121.48M17.0030Trending NewsAnalyst ForecastInsider TradeShort Interest ↑High Trading VolumeTRVITrevi Therapeutics2.8309 of 5 stars$7.60+8.4%$20.11+164.6%+144.8%$925.53MN/A-18.0920News CoveragePositive NewsHigh Trading VolumeTSHATaysha Gene Therapies2.2913 of 5 stars$3.24-3.6%$8.29+155.7%+34.1%$883.87M$8.33M-9.53180News CoverageInsider TradePHATPhathom Pharmaceuticals2.3731 of 5 stars$12.43+0.7%$17.50+40.8%-35.3%$881.78M$55.25M-2.63110Positive NewsIOVAIovance Biotherapeutics4.4317 of 5 stars$2.38-4.4%$11.90+400.0%-78.0%$861.20M$164.07M-1.93500Positive NewsPRAXPraxis Precision Medicines2.2955 of 5 stars$40.75-13.0%$85.88+110.7%-37.0%$857.79M$8.55M-3.32110Positive NewsHigh Trading VolumeAKBAAkebia Therapeutics3.7914 of 5 stars$3.13+5.7%$6.75+115.7%+102.1%$829.89M$160.18M-18.41430News CoveragePositive NewsAnalyst DowngradeAVBPArriVent BioPharma1.9586 of 5 stars$20.21+0.1%$39.14+93.7%-17.0%$819.90MN/A-5.0340Positive NewsHigh Trading VolumeIMNMImmunome2.3386 of 5 stars$9.40-10.6%$22.89+143.5%-42.3%$818.18M$9.04M-3.0540Positive News Related Companies and Tools Related Companies Amylyx Pharmaceuticals Alternatives CorMedix Alternatives Trevi Therapeutics Alternatives Taysha Gene Therapies Alternatives Phathom Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Praxis Precision Medicines Alternatives Akebia Therapeutics Alternatives ArriVent BioPharma Alternatives Immunome Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone thought he was insane…SpaceX just struck a $17 billion deal with EchoStar for radio frequencies, and tech analyst Jeff Brown says it...Brownstone Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYGR Stock Alerts